Core Viewpoint - Morgan Stanley has initiated a "Buy" rating for CRISPR Therapeutics (CRSP.US), highlighting the company's unique advantages in the gene editing field due to its pipeline potential [1] Company Summary - CRISPR Therapeutics is collaborating with Vertex Pharmaceuticals (VRTX.US) to sell the Casgevy in vivo gene editing therapy, providing a faster market entry path through its own immune CAR-T candidates like CTX112 [1] - The company is positioned to attract significant opportunities for its next growth curve with its in vivo technologies targeting ANGPTL3 and Lp(a), especially in the context of the pharmaceutical industry's heightened focus on cardiovascular targets [1] Industry Summary - The pharmaceutical industry is currently placing a strong emphasis on cardiovascular targets, which aligns with CRISPR's strategic focus and resource allocation, allowing it to navigate challenges faced by some of its gene editing peers [1]